No Data
Fosun Pharma Unit's Cancer Drug Gets Orphan Drug Designation From US FDA
Henlius Receives Orphan Drug Designation for Innovative Anti-HER2 MAb HLX22 in the U.S. for Gastric Cancer
Shanghai Henlius Biotech's HLX22 Receives FDA Orphan-drug Designation
HENLIUS (02696.HK): HLX22 has been granted orphan drug designation by the FDA in the USA for the treatment of gastric cancer (GC).
Gelonghui, March 19 – HENLIUS (02696.HK) announced that recently, its wholly-owned subsidiary Henlius USA Inc. received a letter from the USA Food and Drug Administration ("FDA"), stating that HLX22 (recombinant humanized anti-HER2 monoclonal antibody injection) ("HLX22") has been granted orphan drug designation for the treatment of gastric cancer (GC) by the USA FDA. HLX22 is a new targeted therapy licensed from AbClon, Inc. and subsequently developed independently.
Express News | Shanghai Henlius Biotech - Orphan-Drug Designation of Hlx22 (Recombinant Humanized- Anti-Her2 Monoclonal Antibody Injection) Granted by US FDA
Hong Kong stocks fluctuate | HENLIUS (02696) rises over 10% again, nearly 90% increase from early February to now. Hanbatai becomes the fourth product approved for listing overseas by the company.
HENLIUS (02696) has risen over 10% again, with a cumulative increase of nearly 90% in stock price from the beginning of February to now. As of the time of writing, it has risen by 8.75%, priced at 30.45 Hong Kong dollars, with a trading volume of 30.1671 million Hong Kong dollars.
